High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

@article{CarrWilkinson2010HighFO,
  title={High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.},
  author={Jane Carr-Wilkinson and K. O'toole and Katrina M. Wood and Christine Challen and Angela Baker and Julian Board and Laura E. Evans and Michael T. Cole and Nai-Kong V Cheung and Joachim Boos and Gabriele Koehler and Ivo Leuschner and Andrew D. J. Pearson and John Lunec and Deborah A Tweddle},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 4},
  pages={
          1108-18
        }
}
PURPOSE Most neuroblastomas initially respond to therapy but many relapse with chemoresistant disease. p53 mutations are rare in diagnostic neuroblastomas, but we have previously reported inactivation of the p53/MDM2/p14(ARF) pathway in 9 of 17 (53%) neuroblastoma cell lines established at relapse. HYPOTHESIS Inactivation of the p53/MDM2/p14(ARF) pathway develops during treatment and contributes to neuroblastoma relapse. METHODS Eighty-four neuroblastomas were studied from 41 patients with… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 59 CITATIONS, ESTIMATED 53% COVERAGE

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 6 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 52 REFERENCES

Dominant-negative but Clin Cancer Res

SW Wijnhoven, EN Speksnijder, X Liu
  • Cancer Res
  • 2010
VIEW 1 EXCERPT

Antitumor activity of the selective MDM2 antagonist Nutlin-3 against chemoresistant neuroblastoma with wild-type p53

T Van Maerken, L Ferdinande, J Taildeman
  • J Natl Cancer Inst
  • 2009
VIEW 1 EXCERPT